CoChat

BCL-2 system analysis identifies high-risk colorectal cancer patients

Lindner, Andreas U, Salvucci, Manuela, Morgan, Clare, Monsefi, Naser, Resler, Alexa J, Cremona, Mattia, Curry, Sarah, Toomey, Sinead, O'Byrne, Robert, Bacon, Orna, Stühler, Michael, Flanagan, Lorna, Wilson, Richard, Johnston, Patrick G, Salto-Tellez, Manuel, Camilleri-Broët, Sophie, McNamara, Deborah A, Kay, Elaine W, Hennessy, Bryan T, Laurent-Puig, Pierre, Van Schaeybroeck, Sandra, Prehn, Jochen H M · 2017 · Gut

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Objective: The mitochondrial apoptosis pathway is controlled by an interaction of multiple BCL-2 family proteins, and plays a key role in tumour progression and therapy responses. We assessed the prognostic potential of an experimentally validated, mathematical model of BCL-2 protein interactions (DR_MOMP) in patients with stage III colorectal cancer (CRC). Design: Absolute protein levels of BCL-2 family proteins were determined in primary CRC tumours collected from n=128 resected and chemotherapy-treated patients with stage III CRC. We applied DR_MOMP to categorise patients as high or low risk based on model outputs, and compared model outputs with known prognostic factors (T-stage, N-stage, lymphovascular invasion). DR_MOMP signatures were validated on protein of n=156 patients with CRC from the Cancer Genome Atlas (TCGA) project. Results: High-risk stage III patients identified by DR_MOMP had an approximately fivefold increased risk of death compared with patients identified as low risk (HR 5.2, 95% CI 1.4 to 17.9, p=0.02). The DR_MOMP signature ranked highest among all molecular and pathological features analysed. The prognostic signature was validated in the TCGA colon adenocarcinoma (COAD) cohort (HR 4.2, 95% CI 1.1 to 15.6, p=0.04). DR_MOMP also further stratified patients identified by supervised gene expression risk scores into low-risk and high-risk categories. BCL-2-dependent signalling critically contributed to treatment responses in consensus molecular subtypes 1 and 3, linking for the first time specific molecular subtypes to apoptosis signalling. Conclusions: DR_MOMP delivers a system-based biomarker with significant potential as a prognostic tool for stage III CRC that significantly improves established histopathological risk factors.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2016-312287

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 26 references

Cited by

See all 57

Metadata

Authors
Lindner, A. U., Salvucci, M., Morgan, C., Monsefi, N., Resler, A. J., Cremona, M., Curry, S., Toomey, S., O'Byrne, R., Bacon, O., Stühler, M., Flanagan, L., Wilson, R., Johnston, P. G., Salto-Tellez, M., Camilleri-Broët, S., McNamara, D. A., Kay, E. W., Hennessy, B. T., Laurent-Puig, P., Van Schaeybroeck, S., & Prehn, J. H. M.
Affiliations
  • Royal College of Surgeons in Ireland (IE)
  • Departments of Molecular Medicine and Oncology, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Queen's University Belfast (GB)
  • Centre for Cancer Research and Cell Biology, School of Medicine, Queen's University Belfast, Belfast, UK
  • Department of Pathology, Université Paris Descartes, UMR-S 1147, Paris, France
  • UMR-S 1147, Université Paris Descartes, Paris, France, France
Corresponding author
Prehn, Jochen H M
Venue
Gut
Publisher
BMJ
Published
2016-09-23
Volume
66
Issue
12
Pages
2141-2148
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2521503538
Cited by
50
References
26
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 10 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 2 · 2016: 1
FWCI
2.94
Type
journal article
Language
en
Open access
closed
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion)
Funders
  • Seventh Framework Programme (FP7 APO-DECIDE)
  • Science Foundation Ireland (13/IA/1881)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
Bcl-2 family proteins, stage III colorectal cancer, mitochondrial apoptosis, prognostic factors, high-risk patient stratification, consensus molecular subtypes, chemotherapy response, lymphovascular invasion, colon adenocarcinoma
MeSH terms
Adult, Female, Humans, Lymphatic Metastasis, Male, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Survival Rate, Apoptosis, Risk Assessment, Proto-Oncogene Proteins c-bcl-2, Decision Support Systems, Clinical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-2 system analysis identifies high-risk colorectal cancer patients. https://app.cochat.ai/papers/10.1136/gutjnl-2016-312287
The paper
Lindner, A. U., Salvucci, M., Morgan, C., Monsefi, N., Resler, A. J., Cremona, M., Curry, S., Toomey, S., O'Byrne, R., Bacon, O., Stühler, M., Flanagan, L., Wilson, R., Johnston, P. G., Salto-Tellez, M., Camilleri-Broët, S., McNamara, D. A., Kay, E. W., Hennessy, B. T., . . . Prehn, J. H. M. (2017). BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut. https://doi.org/10.1136/gutjnl-2016-312287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.